uniqure NVGene TherapyAMT-130 gets FDA breakthrough therapy designationAmsterdam-based uniQure NV’s gene therapy candidate AMT-130 has been granted FDA Breakthrough Therapy Designation for the treatment of the neurodegenerative Huntington’s disease. more ➔
RijksoverheidGovernanceNetherlands Sets Sights on Global Biotech LeadershipThe Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3 billion in funding. more ➔
123rf.com/guniitaNeurodegenerative DisordersNLS and Kadimastem: Swiss-israeli merger in ALSNLS Pharmaceutics secures US$2m equity funding and signs US$25m equity facility to support merger with Kadimastem (Israel) to combine expertise in aiming to become a leader in regenerative medicine in … more ➔
wikicommonsUnited KingdomUK Government invests millions into new health data serviceUK focuses on digital health research: £600m (US$764m) for new data platform according to the five recommendations of the Sudlow report. more ➔
TIRmed Pharma ABImmunmodulationSwedish TIRmed Pharma raises 4,3m€ against atopic dermatitisTIRmed Pharma secures 4,3m€ to advance immunomodulatory treatment options for atopic dermatitis into clinical development. Stockholm-based TIRmed Pharma has closed this funding round, led by Sciety … more ➔
Menarini GroupPartnershipMenarini and ERBC collaborateFrench ERBC and Menarini Biotech from Italy forge a new strategic alliance to accelerate biopharmaceutical development. more ➔
Freepik.comSwitzerlandSwitzerland needs more efforts in biomedicineIn February 2025, the Federal Office of Public Health (FOPH) announced that the Masterplan in Biomedicine will be discontinued. This sends a troubling signal at a time of growing protectionism and potential … more ➔
BioSpringCDMOBioSpring announces €100+m investment in new synthetic nucleic acid facilityBioSpring GmbH has broken found for one of the world’s largest production facilities for pharmaceutical nucleic acid-based therapeutics. The new high-tech plant will significantly expand the company’s … more ➔
Johnson & JohnsonAntiinflammationMorphosys’ antibody still shining – for J&JThe case of the psoriasis antiinflammation antibody guselkumab is a story of deals and cooperation and selling and buying royalties to fuel other innovation paths. J&J is right in the middle of the game … more ➔
American Academy of Dermatology;doi.org/10.1016/j.jaad.2019.03.056FinancingMoonLake in US$500m debt deal with Hercules CapitalSwiss MoonLake Immunotherapeutics AG has secured up to US$500m in non-dilutive financing from life sciences debt specialist Hercules Capital to finance the potential 2027 launch of sonelokimab in hidradenitis … more ➔
uniqure NV
Rijksoverheid
123rf.com/guniita
wikicommons
TIRmed Pharma AB
Menarini Group
Freepik.com
BioSpring
Johnson & Johnson
American Academy of Dermatology;doi.org/10.1016/j.jaad.2019.03.056